Briggs Morrison

1.9k total citations
23 papers, 1.4k citations indexed

About

Briggs Morrison is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Briggs Morrison has authored 23 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 6 papers in Radiology, Nuclear Medicine and Imaging and 5 papers in Molecular Biology. Recurrent topics in Briggs Morrison's work include Health Systems, Economic Evaluations, Quality of Life (4 papers), Inflammatory mediators and NSAID effects (4 papers) and Cancer-related Molecular Pathways (4 papers). Briggs Morrison is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (4 papers), Inflammatory mediators and NSAID effects (4 papers) and Cancer-related Molecular Pathways (4 papers). Briggs Morrison collaborates with scholars based in United States, United Kingdom and Switzerland. Briggs Morrison's co-authors include Barry J. Gertz, Francesca Catella-Lawson, Brendan McAdam, Garret A. FitzGerald, Kenneth C. Lasseter, Shiv Kapoor, Dean A. Kujubu, Hui Quan, Lisa M. Antes and Philip Leder and has published in prestigious journals such as Journal of Biological Chemistry, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Briggs Morrison

23 papers receiving 1.3k citations

Peers

Briggs Morrison
Sonia Lamontagne Canada
Rebecca B. Rosenstein United States
Ram Sharma United States
Thomas A. Morinelli United States
Charlotte Edenius Sweden
Cinzia Ciccacci Italy
Kenneth B. Pomerantz United States
Ingalill Avis United States
Jonghyeon Kim United States
Nathalie Gérard France
Sonia Lamontagne Canada
Briggs Morrison
Citations per year, relative to Briggs Morrison Briggs Morrison (= 1×) peers Sonia Lamontagne

Countries citing papers authored by Briggs Morrison

Since Specialization
Citations

This map shows the geographic impact of Briggs Morrison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Briggs Morrison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Briggs Morrison more than expected).

Fields of papers citing papers by Briggs Morrison

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Briggs Morrison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Briggs Morrison. The network helps show where Briggs Morrison may publish in the future.

Co-authorship network of co-authors of Briggs Morrison

This figure shows the co-authorship network connecting the top 25 collaborators of Briggs Morrison. A scholar is included among the top collaborators of Briggs Morrison based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Briggs Morrison. Briggs Morrison is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Karakunnel, Joyson, Nam Q. Bui, Latha Palaniappan, et al.. (2018). Reviewing the role of healthy volunteer studies in drug development. Journal of Translational Medicine. 16(1). 336–336. 30 indexed citations
2.
Abbott, Diana, et al.. (2013). Cycle Time Metrics for Multisite Clinical Trials in the United States. Therapeutic Innovation & Regulatory Science. 47(2). 152–160. 14 indexed citations
3.
Nickerson, David, et al.. (2012). Quality by Design in Clinical Trials: A Collaborative Pilot With FDA. Therapeutic Innovation & Regulatory Science. 47(2). 161–166. 9 indexed citations
4.
Getz, Kenneth, Zachary Hallinan, Marla Jo Brickman, et al.. (2012). Meeting the obligation to communicate clinical trial results to study volunteers. Expert Review of Clinical Pharmacology. 5(2). 149–156. 13 indexed citations
5.
Landray, Martin, Cheryl Grandinetti, Judith M. Kramer, et al.. (2012). Clinical Trials: Rethinking How We Ensure Quality. Drug Information Journal. 46(6). 657–660. 15 indexed citations
6.
Morrison, Briggs, An Liu, Jules T. Mitchel, et al.. (2011). Monitoring the quality of conduct of clinical trials: a survey of current practices. Clinical Trials. 8(3). 342–349. 60 indexed citations
7.
Brunner, Thomas, Eric J. Bernhard, Thomas F. DeLaney, et al.. (2004). A phase I trial of the farnesyltransferase and geranylgeranyltransferase-I inhibitor L-778,123 (L-778) and radiotherapy for locally advanced pancreatic cancer. Journal of Clinical Oncology. 22(14_suppl). 4098–4098. 2 indexed citations
8.
Martin, Neil E., Thomas Brunner, Thomas F. DeLaney, et al.. (2004). A Phase I Trial of the Dual Farnesyltransferase and Geranylgeranyltransferase Inhibitor L-778,123 and Radiotherapy for Locally Advanced Pancreatic Cancer. Clinical Cancer Research. 10(16). 5447–5454. 67 indexed citations
9.
10.
Hahn, Stephen M., Eric J. Bernhard, William F. Regine, et al.. (2002). A Phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer.. PubMed. 8(5). 1065–72. 72 indexed citations
11.
Hahn, Seung Min, Briggs Morrison, Majid Mohiuddin, et al.. (2000). Phase I trial of the farnesyl protein transferase (FPTASE) inhibitor L-778123 in combination with radiotherapy. Clinical Cancer Research. 6. 1 indexed citations
12.
Morrison, Briggs, James R. Fricke, J. Brown, et al.. (2000). THE OPTIMAL ANALGESIC DOSE OF ROFECOXIB: OVERVIEW OF SIX RANDOMIZED CONTROLLED TRIALS. The Journal of the American Dental Association. 131(12). 1729–1737. 44 indexed citations
13.
Morrison, Briggs, et al.. (1999). Targeting HER-2/neu for active-specific immunotherapy in a mouse model of spontaneous breast cancer. International Journal of Cancer. 83(3). 393–400. 45 indexed citations
14.
Ehrich, Elliot, Thomas J. Schnitzer, Harris McIlwain, et al.. (1999). Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group.. PubMed. 26(11). 2438–47. 132 indexed citations
15.
Morrison, Briggs, et al.. (1999). Rofecoxib, a Specific Cyclooxygenase-2 Inhibitor, in Primary Dysmenorrhea. Obstetrics and Gynecology. 94(4). 504–508. 8 indexed citations
16.
Céfaï, Daniel, et al.. (1999). Targeting HER‐2/neu for active‐specific immunotherapy in a mouse model of spontaneous breast cancer. International Journal of Cancer. 83(3). 393–400. 1 indexed citations
17.
Gimmi, Claude, Briggs Morrison, B. Mainprice, et al.. (1996). Breast cancer–associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nature Medicine. 2(12). 1367–1370. 142 indexed citations
18.
Morrison, Briggs, J. Randall Moorman, Gopal C. Kowdley, et al.. (1995). Mat-8, a Novel Phospholemman-like Protein Expressed in Human Breast Tumors, Induces a Chloride Conductance in Xenopus Oocytes. Journal of Biological Chemistry. 270(5). 2176–2182. 131 indexed citations
19.
Morrison, Briggs & Philip Leder. (1992). A receptor binding domain of mouse interleukin-4 defined by a solid-phase binding assay and in vitro mutagenesis.. Journal of Biological Chemistry. 267(17). 11957–11963. 39 indexed citations
20.
Morrison, Briggs. (1989). Using news broadcasts for authentic listening comprehension. ELT Journal. 43(1). 14–18. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sonia Lamontagne Breakdown of academic impact, for papers by Rebecca B. Rosenstein Breakdown of academic impact, for papers by Ram Sharma Breakdown of academic impact, for papers by Thomas A. Morinelli Breakdown of academic impact, for papers by Charlotte Edenius Breakdown of academic impact, for papers by Cinzia Ciccacci Breakdown of academic impact, for papers by Kenneth B. Pomerantz Breakdown of academic impact, for papers by Ingalill Avis Breakdown of academic impact, for papers by Jonghyeon Kim Breakdown of academic impact, for papers by Nathalie Gérard
Rankless by CCL
2026